NYSE:ZTSPharmaceuticals
How EMA’s Positive Opinion on Portela Could Shape Zoetis's (ZTS) Innovation and Growth Potential
Earlier this week, Zoetis announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products has issued a positive opinion recommending marketing authorization for Portela®, a novel monoclonal antibody therapy designed to provide three months of pain relief for cats with osteoarthritis.
If approved, Portela would become the first long-acting anti-nerve growth factor monoclonal antibody therapy for cats, representing a significant innovation for feline osteoarthritis...